Cinacalcet
A calcimimetic agent that increases the sensitivity of the calcium-sensing receptor on parathyroid cells to extracellular calcium, thereby reducing parathyroid hormone (PTH) secretion. It is used to treat secondary hyperparathyroidism in dialysis patients and hypercalcemia in parathyroid carcinoma. Hypocalcemia is an important adverse effect that requires monitoring of serum calcium levels.
Moleküler Ağırlık
357,4000 g/mol
LogP
6,10
TPSA
12,00 Ų
Lipinski RO5
Geçer
Terapötik Alanlar
Etki Mekanizması
Mimics or modulates parathyroid hormone activity to stimulate osteoblast-mediated bone formation, increasing bone mineral density and reducing fracture risk.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Mimics or modulates parathyroid hormone activity to stimulate osteoblast-mediated bone formation, increasing bone mineral density and reducing fracture risk.
2D Yapı
Cite this structure
Embed this structure
SMILES
C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1cccc2ccccc12
InChI
InChI=1S/C22H22F3N/c1-16(20-13-5-10-18-9-2-3-12-21(18)20)26-14-6-8-17-7-4-11-19(15-17)22(23,24)25/h2-5,7,9-13,15-16,26H,6,8,14H2,1H3/t16-/m1/s1
Molecular Formula
C22H22F3N
HBD / HBA
1 / 4
Döndürülebilir Bağlar
6
Ağır Atomlar
26
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Sıkça Sorulan Sorular
A calcimimetic agent that increases the sensitivity of the calcium-sensing receptor on parathyroid cells to extracellular calcium, thereby reducing parathyroid hormone (PTH) secretion. It is used to treat secondary hyperparathyroidism in dialysis patients and hypercalcemia in parathyroid carcinoma. Hypocalcemia is an important adverse effect that requires monitoring of serum calcium levels.
Mimics or modulates parathyroid hormone activity to stimulate osteoblast-mediated bone formation, increasing bone mineral density and reducing fracture risk.
Yes, Cinacalcet is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201284. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 156419. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="cinacalcet"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/cinacalcet/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/cinacalcet/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/cinacalcet/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="cinacalcet"></drugfyi-drug>